Glutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
about
Glutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
description
clinical trial
@en
klinisch onderzoek
@nl
name
Glutaminase Inhibitor CB-839 H ...... IV Non-small Cell Lung Cancer
@en
type
label
Glutaminase Inhibitor CB-839 H ...... IV Non-small Cell Lung Cancer
@en
prefLabel
Glutaminase Inhibitor CB-839 H ...... IV Non-small Cell Lung Cancer
@en
P1050
P1476
A Phase I/II Study of AZD9291 ...... ant Non-Small Cell Lung Cancer
@en
P3098
NCT03831932
P4844
P580
2019-05-02T00:00:00Z
P582
2021-06-01T00:00:00Z